Progress and Perspectives on HIV-1 microbicide development

Virology

Volumn 497, Issue , 2016, Pages 69-80

  Alexandre, Kabamba B ^a   Mufhandu, Hazel T ^a   London, Grace M ^b   Chakauya, E ^a   Khati, M ^a,c  

^a DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^b Department of Health Free State District Health Services and Health Programs ^*  (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HIV 1; Microbicides; Prevention; Sexual transmission

Indexed keywords

1 (3 CYCLOPENTENYLMETHYL) 6 (3,5 DIMETHYLBENZOYL) 5 ETHYLURACIL; ASTODRIMER; BETA CYCLODEXTRIN; C 31G; CARBOSILANE DENDRIMER; CELLACEFATE; CELLULOSE SULFATE; CYANOVIRIN N; DAPIVIRINE; DENDRIMER; DODECYL SULFATE SODIUM; GLYCOPROTEIN GP 120; GRIFFITHSIN; LECTIN; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NANOPARTICLE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONOXINOL 9; NUCLEIC ACID; PLACEBO; POKEWEED ANTIVIRUS PROTEIN; POLYANION; PRO 2000; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCYTOVIRIN; SPERMICIDAL AGENT; SURFACTANT; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIINFECTIVE AGENT; DRUG CARRIER;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL ACTIVITY; CONTROLLED RELEASE FORMULATION; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ERYTHEMA; FEMALE GENITAL SYSTEM; FILM; GEL; GENITAL ULCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; NONHUMAN; PETECHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEXUAL INTERCOURSE; SUPPOSITORY; TABLET; TREATMENT FAILURE; VAGINA RING; VIRUS TRANSMISSION; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; FEMALE; HIV INFECTIONS; MALE; MUCOSA; PHYSIOLOGY; SEXUALLY TRANSMITTED DISEASES, VIRAL; TRANSMISSION; VIROLOGY;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUCOUS MEMBRANE; SEXUALLY TRANSMITTED DISEASES, VIRAL;

EID: 84978254031     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2016.07.004     Document Type: Review

References (200)

1. Abbas, W., Tariq, M., Iqbal, M., Kumar, A., Herbein, G., Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?. Viruses 7 (2015), 1578–1598.
2. Abdool Karim, Q., Abdool Karim, S.S., Frohlich, J.A., Grobler, A.C., Baxter, C., Mansoor, L.E., Kharsany, A.B., Sibeko, S., Mlisana, K.P., Omar, Z., Gengiah, T.N., Maarschalk, S., Arulappan, N., Mlotshwa, M., Morris, L., Taylor, D., Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329 (2010), 1168–1174.
3. Abdool Karim, S.S., Richardson, B.A., Ramjee, G., Hoffman, I.F., Chirenje, Z.M., Taha, T., Kapina, M., Maslankowski, L., Coletti, A., Profy, A., Moench, T.R., Piwowar-Manning, E., Masse, B., Hillier, S.L., Soto-Torres, L., Team, H.I.V.P.T.N.S., Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25 (2011), 957–966.
4. Acarturk, F., Parlatan, Z.I., Saracoglu, O.F., Comparison of vaginal aminopeptidase enzymatic activities in various animals and in humans. J. Pharm. Pharmacol. 53 (2001), 1499–1504.
5. Agace, W.W., Amara, A., Roberts, A.I., Pablos, J.L., Thelen, S., Uguccioni, M., Li, X.Y., Marsal, J., Arenzana-Seisdedos, F., Delaunay, T., Ebert, E.C., Moser, B., Parker, C.M., Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr. Biol. 10 (2000), 325–328.
6. Akil, A., Parniak, M.A., Dezzuitti, C.S., Moncla, B.J., Cost, M.R., Li, M., Rohan, L.C., Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv. Transl. Res. 1 (2011), 209–222.
7. Aldunate, M., Tyssen, D., Johnson, A., Zakir, T., Sonza, S., Moench, T., Cone, R., Tachedjian, G., Vaginal concentrations of lactic acid potently inactivate HIV. J. Antimicrob. Chemother. 68 (2013), 2015–2025.
8. Alexandre, K.B., Gray, E.S., Lambson, B.E., Moore, P.L., Choge, I.A., Mlisana, K., Karim, S.S., McMahon, J., O'Keefe, B., Chikwamba, R., Morris, L., Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology 402 (2010), 187–196.
9. Alexandre, K.B., Gray, E.S., Pantophlet, R., Moore, P.L., McMahon, J.B., Chakauya, E., O'Keefe, B.R., Chikwamba, R., Morris, L., Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J. Virol., 2011.
10. Alexandre, K.B., Moore, P.L., Nonyane, M., Gray, E.S., Ranchobe, N., Chakauya, E., McMahon, J.B., O'Keefe, B.R., Chikwamba, R., Morris, L., Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Virology 446 (2013), 66–76.
11. Amaral, E., Faundes, A., Zaneveld, L., Waller, D., Garg, S., Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. Contraception 60 (1999), 361–366.
12. Amaral, E., Perdigao, A., Souza, M.H., Mauck, C., Waller, D., Zaneveld, L., Faundes, A., Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception 73 (2006), 542–547.
13. Ambrose, Z., Compton, L., Piatak, M. Jr., Lu, D., Alvord, W.G., Lubomirski, M.S., Hildreth, J.E., Lifson, J.D., Miller, C.J., KewalRamani, V.N., Incomplete protection against simian immunodeficiency virus vaginal transmission in rhesus macaques by a topical antiviral agent revealed by repeat challenges. J. Virol. 82 (2008), 6591–6599.
14. Aquaro, S., Calio, R., Balzarini, J., Bellocchi, M.C., Garaci, E., Perno, C.F., Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antivir. Res. 55 (2002), 209–225.
15. Arrighi, J.F., Pion, M., Garcia, E., Escola, J.M., van Kooyk, Y., Geijtenbeek, T.B., Piguet, V., DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J. Exp. Med. 200 (2004), 1279–1288.
16. Baeten, J.M., Palanee-Phillips, T., Brown, E.R., Schwartz, K., Soto-Torres, L.E., Govender, V., Mgodi, N.M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., Siva, S., Bekker, L.G., Jeenarain, N., Gaffoor, Z., Martinson, F., Makanani, B., Pather, A., Naidoo, L., Husnik, M., Richardson, B.A., Parikh, U.M., Mellors, J.W., Marzinke, M.A., Hendrix, C.W., van der Straten, A., Ramjee, G., Chirenje, Z.M., Nakabiito, C., Taha, T.E., Jones, J., Mayo, A., Scheckter, R., Berthiaume, J., Livant, E., Jacobson, C., Ndase, P., White, R., Patterson, K., Germuga, D., Galaska, B., Bunge, K., Singh, D., Szydlo, D.W., Montgomery, E.T., Mensch, B.S., Torjesen, K., Grossman, C.I., Chakhtoura, N., Nel, A., Rosenberg, Z., McGowan, I., Hillier, S., Team, M.-A.S., Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N. Engl. J. Med., 2016.
17. Ball, C., Chou, S.F., Jiang, Y., Woodrow, K.A., Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc. Mater. Sci. Eng. C: Mater. Biol. Appl. 63 (2016), 117–124.
18. Ball, C., Krogstad, E., Chaowanachan, T., Woodrow, K.A., Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS One, 7, 2012, e49792.
19. Ball, C., Woodrow, K.A., Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV. Antimicrob. Agents Chemother. 58 (2014), 4855–4865.
20. Ballweber, L., Robinson, B., Kreger, A., Fialkow, M., Lentz, G., McElrath, M.J., Hladik, F., Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells. J. Virol. 85 (2011), 13443–13447.
21. Balzarini, J., Hao, Z., Herdewijn, P., Johns, D.G., De Clercq, E., Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. USA 88 (1991), 1499–1503.
22. Balzarini, J., Naesens, L., Verbeken, E., Laga, M., Van Damme, L., Parniak, M., Van Mellaert, L., Anne, J., De Clercq, E., Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. Aids 12 (1998), 1129–1138.
23. Balzarini, J., Van Laethem, K., Peumans, W.J., Van Damme, E.J., Bolmstedt, A., Gago, F., Schols, D., Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J. Virol. 80 (2006), 8411–8421.
24. Barnard, J., Borkow, G., Parniak, M.A., The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 36 (1997), 7786–7792.
25. Barouch, D.H., Klasse, P.J., Dufour, J., Veazey, R.S., Moore, J.P., Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc. Natl. Acad. Sci. USA 109 (2012), 8694–8698.
26. Bayer, L.L., Jensen, J.T., ACIDFORM: a review of the evidence. Contraception 90 (2014), 11–18.
27. Bhoopat, L., Eiangleng, L., Rugpao, S., Frankel, S.S., Weissman, D., Lekawanvijit, S., Petchjom, S., Thorner, P., Bhoopat, T., In vivo identification of Langerhans and related dendritic cells infected with HIV-1 subtype E in vaginal mucosa of asymptomatic patients. Mod. Pathol.: Off. J. U.S. Can. Acad. Pathol. Inc. 14 (2001), 1263–1269.
28. Bibby, D.C., Davies, N.M., Tucker, I.G., Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int. J. Pharm. 197 (2000), 1–11.
29. Blakney, A.K., Ball, C., Krogstad, E.A., Woodrow, K.A., Electrospun fibers for vaginal anti-HIV drug delivery. Antivir. Res 100:Suppl (2013), S9–S16.
30. Bobardt, M.D., Chatterji, U., Schaffer, L., de Witte, L., Gallay, P.A., Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob. Agents Chemother. 54 (2010), 2753–2766.
31. Bobardt, M.D., Chatterji, U., Selvarajah, S., Van der Schueren, B., David, G., Kahn, B., Gallay, P.A., Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J. Virol. 81 (2007), 395–405.
32. Bollen, L.J., Blanchard, K., Kilmarx, P.H., Chaikummao, S., Connolly, C., Wasinrapee, P., Srivirojana, N., Achalapong, J., Tappero, J.W., McNicholl, J.M., No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebo-controlled randomized clinical trial. J. Acquir. Immune Defic. Syndr. 47 (2008), 253–257.
33. Bomsel, M., Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3 (1997), 42–47.
34. Borkow, G., Barnard, J., Nguyen, T.M., Belmonte, A., Wainberg, M.A., Parniak, M.A., Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 71 (1997), 3023–3030.
35. Bourne, N., Stanberry, L.R., Kern, E.R., Holan, G., Matthews, B., Bernstein, D.I., Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob. Agents Chemother. 44 (2000), 2471–2474.
36. Bunge, K.E., Dezzutti, C.S., Rohan, L.C., Hendrix, C.W., Marzinke, M.A., Richardson-Harman, N., Moncla, B.J., Devlin, B., Meyn, L.A., Spiegel, H.M., Hillier, S.L., A phase 1 trial to assess the safety, acceptability, pharmacokinetics, and pharmacodynamics of a novel dapivirine vaginal film. J. Acquir. Immune Defic. Syndr. 71 (2016), 498–505.
37. Bunka, D.H., Stockley, P.G., Aptamers come of age - at last. Nat. Rev. Microbiol. 4 (2006), 588–596.
38. Calis, S., Yulug, N., Sumnu, M., Ayhan, A., Hincal, A.A., A non-antibiotic antimicrobial mixture (C31G): evaluation of the antimicrobial efficiency of C31G on vaginal cultures. Boll. Chim. Farm 131 (1992), 335–338.
39. Chen, B.A., Panther, L., Marzinke, M.A., Hendrix, C.W., Hoesley, C.J., van der Straten, A., Husnik, M.J., Soto-Torres, L., Nel, A., Johnson, S., Richardson-Harman, N., Rabe, L.K., Dezzutti, C.S., Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: a double-blind randomized trial. J. Acquir. Immune Defic. Syndr. 70 (2015), 242–249.
40. Coggins, C., Blanchard, K., Alvarez, F., Brache, V., Weisberg, E., Kilmarx, P.H., Lacarra, M., Massai, R., Mishell, D. Jr., Salvatierra, A., Witwatwongwana, P., Elias, C., Ellertson, C., Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex. Transm. Infect. 76 (2000), 480–483.
41. Cohen, C., Forzan, M., Sproat, B., Pantophlet, R., McGowan, I., Burton, D., James, W., An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology 381 (2008), 46–54.
42. Cohen, M.S., Britigan, B.E., French, M., Bean, K., Preliminary observations on lactoferrin secretion in human vaginal mucus: variation during the menstrual cycle, evidence of hormonal regulation, and implications for infection with Neisseria gonorrhoeae. Am. J. Obstet. Gynecol. 157 (1987), 1122–1125.
43. Coombs, R.W., Reichelderfer, P.S., Landay, A.L., Recent observations on HIV type-1 infection in the genital tract of men and women. Aids 17 (2003), 455–480.
44. Cummins, J.E. Jr., Guarner, J., Flowers, L., Guenthner, P.C., Bartlett, J., Morken, T., Grohskopf, L.A., Paxton, L., Dezzutti, C.S., Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob. Agents Chemother. 51 (2007), 1770–1779.
45. Cutler, B., Justman, J., Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 8 (2008), 685–697.
46. das Neves, J., Bahia, M.F., Gels as vaginal drug delivery systems. Int. J. Pharm. 318 (2006), 1–14.
47. De Clercq, E., Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem. Pharm. 73 (2007), 911–922.
48. de Witte, L., Nabatov, A., Pion, M., Fluitsma, D., de Jong, M.A., de Gruijl, T., Piguet, V., van Kooyk, Y., Geijtenbeek, T.B., Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat. Med. 13 (2007), 367–371.
49. Devlin, B., Nuttall, J., Wilder, S., Woodsong, C., Rosenberg, Z., Development of dapivirine vaginal ring for HIV. Prev. Antivir. Res. 100:Suppl (2013), S3–S8.
50. Dey, A.K., Khati, M., Tang, M., Wyatt, R., Lea, S.M., James, W., An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J. Virol. 79 (2005), 13806–13810.
51. Dezzutti, C.S., Guenthner, P.C., Cummins, J.E. Jr., Cabrera, T., Marshall, J.H., Dillberger, A., Lal, R.B., Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J. Infect. Dis. 183 (2001), 1204–1213.
52. Doms, R.W., Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 276 (2000), 229–237.
53. Doms, R.W., Trono, D., The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 14 (2000), 2677–2688.
54. Edwards, J.N., Morris, H.B., Langerhans' cells and lymphocyte subsets in the female genital tract. Br. J. Obstet. Gynaecol. 92 (1985), 974–982.
55. Elias, C., Coggins, C., Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: where have we been? Where are we going?. J. Women's Health Gend.-Based Med. 10 (2001), 163–173.
56. Elias, C.J., Coggins, C., Female-controlled methods to prevent sexual transmission of HIV. Aids 10:Suppl. 3 (1996), S43–S51.
57. Ellington, A.D., Szostak, J.W., In vitro selection of RNA molecules that bind specific ligands. Nature 346 (1990), 818–822.
58. Ferir, G., Huskens, D., Palmer, K.E., Boudreaux, D.M., Swanson, M.D., Markovitz, D.M., Balzarini, J., Schols, D., Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains. AIDS Res. Hum. Retrovir. 28 (2012), 1513–1523.
59. Ferir, G., Palmer, K.E., Schols, D., Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology 417 (2011), 253–258.
60. Garg, S., Kandarapu, R., Vermani, K., Tambwekar, K.R., Garg, A., Waller, D.P., Zaneveld, L.J., Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care STDs 17 (2003), 17–32.
61. Geijtenbeek, T.B., Kwon, D.S., Torensma, R., van Vliet, S.J., van Duijnhoven, G.C., Middel, J., Cornelissen, I.L., Nottet, H.S., KewalRamani, V.N., Littman, D.R., Figdor, C.G., van Kooyk, Y., DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100 (2000), 587–597.
62. Graham, D.R., Chertova, E., Hilburn, J.M., Arthur, L.O., Hildreth, J.E., Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. J. Virol. 77 (2003), 8237–8248.
63. Greenhead, P., Hayes, P., Watts, P.S., Laing, K.G., Griffin, G.E., Shattock, R.J., Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J. Virol. 74 (2000), 5577–5586.
64. Gupta, K.M., Pearce, S.M., Poursaid, A.E., Aliyar, H.A., Tresco, P.A., Mitchnik, M.A., Kiser, P.F., Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J. Pharm. Sci. 97 (2008), 4228–4239.
65. Ham, A.S., Cost, M.R., Sassi, A.B., Dezzutti, C.S., Rohan, L.C., Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res 26 (2009), 502–511.
66. Herrera, C., Armanasco, N., Garcia-Perez, J., Ziprin, P., Olejniczak, N., Alcami, J., Nuttall, J., Shattock, R.J., Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates. AIDS 30 (2016), 1015–1025.
67. Hladik, F., Burgener, A., Ballweber, L., Gottardo, R., Vojtech, L., Fourati, S., Dai, J.Y., Cameron, M.J., Strobl, J., Hughes, S.M., Hoesley, C., Andrew, P., Johnson, S., Piper, J., Friend, D.R., Ball, T.B., Cranston, R.D., Mayer, K.H., McElrath, M.J., McGowan, I., Mucosal effects of tenofovir 1% gel. eLife, 4, 2015.
68. Hladik, F., Lentz, G., Akridge, R.E., Peterson, G., Kelley, H., McElroy, A., McElrath, M.J., Dendritic cell-T-cell interactions support coreceptor-independent human immunodeficiency virus type 1 transmission in the human genital tract. J. Virol. 73 (1999), 5833–5842.
69. Hladik, F., Lentz, G., Delpit, E., McElroy, A., McElrath, M.J., Coexpression of CCR5 and IL-2 in human genital but not blood T cells: implications for the ontogeny of the CCR5+ Th1 phenotype. J. Immunol. 163 (1999), 2306–2313.
70. Hladik, F., McElrath, M.J., Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8 (2008), 447–457.
71. Hladik, F., Sakchalathorn, P., Ballweber, L., Lentz, G., Fialkow, M., Eschenbach, D., McElrath, M.J., Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26 (2007), 257–270.
72. Hope, T.J., Bridging efficient viral infection. Nat. Cell Biol. 9 (2007), 243–244.
73. Hu, J., Gardner, M.B., Miller, C.J., Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74 (2000), 6087–6095.
74. Hu, J., Pope, M., Brown, C., O'Doherty, U., Miller, C.J., Immunophenotypic characterization of simian immunodeficiency virus-infected dendritic cells in cervix, vagina, and draining lymph nodes of rhesus monkeys. Lab. Investig. 78 (1998), 435–451.
75. Huang, C., Soenen, S.J., van Gulck, E., Vanham, G., Rejman, J., Van Calenbergh, S., Vervaet, C., Coenye, T., Verstraelen, H., Temmerman, M., Demeester, J., De Smedt, S.C., Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery. Biomaterials 33 (2012), 962–969.
76. Jain, M., Zhang, L., Patterson, E.E., Kebebew, E., KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. PLoS One, 6, 2011, e26866.
77. James, W., Nucleic acid and polypeptide aptamers: a powerful approach to ligand discovery. Curr. Opin. Pharm. 1 (2001), 540–546.
78. Jameson, B., Baribaud, F., Pohlmann, S., Ghavimi, D., Mortari, F., Doms, R.W., Iwasaki, A., Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J. Virol. 76 (2002), 1866–1875.
79. Jarrett, A.M., Gao, Y., Hussaini, M.Y., Cogan, N.G., Katz, D.F., Sensitivity analysis of a pharmacokinetic model of vaginal anti-HIV microbicide drug delivery. J. Pharm. Sci. 105 (2016), 1772–1778.
80. Jayasena, S.D., Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 45 (1999), 1628–1650.
81. Jiang, Y.H., Emau, P., Cairns, J.S., Flanary, L., Morton, W.R., McCarthy, T.D., Tsai, C.C., SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retrovir. 21 (2005), 207–213.
82. Johansson, E.L., Rudin, A., Wassen, L., Holmgren, J., Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology 96 (1999), 272–277.
83. Jolly, C., Sattentau, Q.J., Retroviral spread by induction of virological synapses. Traffic 5 (2004), 643–650.
84. Jolly, C., Sattentau, Q.J., Human immunodeficiency virus type 1 assembly, budding, and cell-cell spread in T cells take place in tetraspanin-enriched plasma membrane domains. J. Virol. 81 (2007), 7873–7884.
85. Kawamura, T., Koyanagi, Y., Nakamura, Y., Ogawa, Y., Yamashita, A., Iwamoto, T., Ito, M., Blauvelt, A., Shimada, S., Significant virus replication in Langerhans cells following application of HIV to abraded skin: relevance to occupational transmission of HIV. J. Immunol. 180 (2008), 3297–3304.
86. Kell, P.D., Barton, S.E., Edmonds, D.K., Boag, F.C., HIV infection in a patient with Meyer-Rokitansky-Kuster-Hauser syndrome. J. R. Soc. Med 85 (1992), 706–707.
87. Khati, M., Schuman, M., Ibrahim, J., Sattentau, Q., Gordon, S., James, W., Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers. J. Virol. 77 (2003), 12692–12698.
88. Khoury, A.N., Zhou, Q.P., Gorenberg, D.M., Nies, B.M., Manley, G.E., Mecklenburg, F.E., A comparison of intermittent vaginal administration of two different doses of misoprostol suppositories with continuous dinoprostone for cervical ripening and labor induction. J. Matern.-Fetal Med. 10 (2001), 186–192.
89. Kilsdonk, E.P., Yancey, P.G., Stoudt, G.W., Bangerter, F.W., Johnson, W.J., Phillips, M.C., Rothblat, G.H., Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem. 270 (1995), 17250–17256.
90. Kouokam, J.C., Huskens, D., Schols, D., Johannemann, A., Riedell, S.K., Walter, W., Walker, J.M., Matoba, N., O'Keefe, B.R., Palmer, K.E., Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS One, 6, 2011, e22635.
91. Kraus, E., James, W., Barclay, A.N., Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. J. Immunol. 160 (1998), 5209–5212.
92. Krebs, F.C., Miller, S.R., Malamud, D., Howett, M.K., Wigdahl, B., Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antivir. Res. 43 (1999), 157–173.
93. Lakshmi, Y.S., Kumar, P., Kishore, G., Bhaskar, C., Kondapi, A.K., Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles. Sci. Rep., 6, 2016, 25479.
94. Lederman, M.M., Offord, R.E., Hartley, O., Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6 (2006), 371–382.
95. Lederman, M.M., Veazey, R.S., Offord, R., Mosier, D.E., Dufour, J., Mefford, M., Piatak, M. Jr., Lifson, J.D., Salkowitz, J.R., Rodriguez, B., Blauvelt, A., Hartley, O., Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306 (2004), 485–487.
96. Liao, Z., Cimakasky, L.M., Hampton, R., Nguyen, D.H., Hildreth, J.E., Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res. Hum. Retrovir. 17 (2001), 1009–1019.
97. Lobritz, M.A., Ratcliff, A.N., Marozsan, A.J., Dudley, D.M., Tilton, J.C., Arts, E.J., Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc. Antimicrob. Agents Chemother. 57 (2013), 2640–2650.
98. MacQueen, K.M., Dlamini, S., Perry, B., Okumu, E., Sortijas, S., Singh, C., Pillay, D., Majors, A., Jerome, S., Watson, S., Karim, S.A., Karim, Q.A., Mansoor, L.E., 2016. Social context of adherence in an open-label 1% tenofovir gel trial: gender dynamics and disclosure in kwazulu-natal, South Africa. AIDS Behav.
99. Maeda, K., Das, D., Nakata, H., Mitsuya, H., CCR5 inhibitors: emergence, success, and challenges. Expert Opin. Emerg. drugs 17 (2012), 135–145.
100. Mahalingam, A., Simmons, A.P., Ugaonkar, S.R., Watson, K.M., Dezzutti, C.S., Rohan, L.C., Buckheit, R.W. Jr., Kiser, P.F., Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob. Agents Chemother. 55 (2011), 1650–1660.
101. Maher, D., Wu, X., Schacker, T., Horbul, J., Southern, P., HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc. Natl. Acad. Sci. USA 102 (2005), 11504–11509.
102. Malcolm, R.K., Edwards, K.L., Kiser, P., Romano, J., Smith, T.J., Advances in microbicide vaginal rings. Antivir. Res 88:Suppl. 1 (2010), S30–S39.
103. Malcolm, R.K., Forbes, C.J., Geer, L., Veazey, R.S., Goldman, L., Klasse, P.J., Moore, J.P., Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J. Antimicrob. Chemother. 68 (2013), 678–683.
104. Malcolm, R.K., Veazey, R.S., Geer, L., Lowry, D., Fetherston, S.M., Murphy, D.J., Boyd, P., Major, I., Shattock, R.J., Klasse, P.J., Doyle, L.A., Rasmussen, K.K., Goldman, L., Ketas, T.J., Moore, J.P., Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob. Agents Chemother. 56 (2012), 2251–2258.
105. Malonza, I.M., Mirembe, F., Nakabiito, C., Odusoga, L.O., Osinupebi, O.A., Hazari, K., Chitlange, S., Ali, M.M., Callahan, M., Van Damme, L., Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. Aids 19 (2005), 2157–2163.
106. Marechal, V., Prevost, M.C., Petit, C., Perret, E., Heard, J.M., Schwartz, O., Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis. J. Virol. 75 (2001), 11166–11177.
107. Marrazzo, J.M., Ramjee, G., Richardson, B.A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., Hendrix, C.W., Dai, J.Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U.M., Piper, J., Masse, B., Grossman, C., Rooney, J., Schwartz, J.L., Watts, H., Marzinke, M.A., Hillier, S.L., McGowan, I.M., Chirenje, Z.M., Team, V.S., Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med 372 (2015), 509–518.
108. Marx, P.A., Spira, A.I., Gettie, A., Dailey, P.J., Veazey, R.S., Lackner, A.A., Mahoney, C.J., Miller, C.J., Claypool, L.E., Ho, D.D., Alexander, N.J., Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2 (1996), 1084–1089.
109. Mayer, K.H., Peipert, J., Fleming, T., Fullem, A., Moench, T., Cu-Uvin, S., Bentley, M., Chesney, M., Rosenberg, Z., Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin. Infect. Dis. 32 (2001), 476–482.
110. Mbopi-Keou, F.X., Trottier, S., Omar, R.F., Nkele, N.N., Fokoua, S., Mbu, E.R., Domingo, M.C., Giguere, J.F., Piret, J., Mwatha, A., Masse, B., Bergeron, M.G., A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women. Contraception 81 (2010), 79–85.
111. Mbopi-Keou, F.X., Trottier, S., Omar, R.F., Nkele, N.N., Fokoua, S., Mbu, E.R., Giguere, J.F., Domingo, M.C., Piret, J., Tsague, L., Zekeng, L., Mwatha, A., Masse, B., Bergeron, M.G., A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon. Contraception 80 (2009), 484–492.
112. McConville, C., Major, I., Devlin, B., Brimer, A., Development of a multi-layered vaginal tablet containing dapivirine, levonorgestrel and acyclovir for use as a multipurpose prevention technology. Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2016.
113. McConville, C., Smith, J.M., McCoy, C.F., Srinivasan, P., Mitchell, J., Holder, A., Otten, R.A., Butera, S., Doncel, G.F., Friend, D.R., Malcolm, R.K., Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques. Drug Deliv. Transl. Res. 5 (2015), 27–37.
114. McCormack, S., Ramjee, G., Kamali, A., Rees, H., Crook, A.M., Gafos, M., Jentsch, U., Pool, R., Chisembele, M., Kapiga, S., Mutemwa, R., Vallely, A., Palanee, T., Sookrajh, Y., Lacey, C.J., Darbyshire, J., Grosskurth, H., Profy, A., Nunn, A., Hayes, R., Weber, J., PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376 (2010), 1329–1337.
115. McDonald, D., Wu, L., Bohks, S.M., KewalRamani, V.N., Unutmaz, D., Hope, T.J., Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 300 (2003), 1295–1297.
116. McElrath, M.J., Ballweber, L., Terker, A., Kreger, A., Sakchalathorn, P., Robinson, B., Fialkow, M., Lentz, G., Hladik, F., Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrob. Agents Chemother. 54 (2010), 763–772.
117. McGowan, I., Gomez, K., Bruder, K., Febo, I., Chen, B.A., Richardson, B.A., Husnik, M., Livant, E., Price, C., Jacobson, C., Team, M.T.N.P., Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 25 (2011), 1057–1064.
118. McNamara, J.O. 2nd, Andrechek, E.R., Wang, Y., Viles, K.D., Rempel, R.E., Gilboa, E., Sullenger, B.A., Giangrande, P.H., Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24 (2006), 1005–1015.
119. Melikyan, G.B., Markosyan, R.M., Hemmati, H., Delmedico, M.K., Lambert, D.M., Cohen, F.S., Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151 (2000), 413–423.
120. Mensch, B.S., Brown, E.R., Liu, K., Marrazzo, J., Chirenje, Z.M., Gomez, K., Piper, J., Patterson, K., van der Straten, A., Reporting of adherence in the VOICE trial: did disclosure of product nonuse increase at the termination visit?. AIDS Behav., 2016.
121. Miller, C.J., Marthas, M., Torten, J., Alexander, N.J., Moore, J.P., Doncel, G.F., Hendrickx, A.G., Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J. Virol. 68 (1994), 6391–6400.
122. Miller, C.J., McGhee, J.R., Gardner, M.B., Mucosal immunity, HIV transmission, and AIDS. Lab. Investig. 68 (1993), 129–145.
123. Miller, C.J., Shattock, R.J., Target cells in vaginal HIV transmission. Microbes Infect. 5 (2003), 59–67.
124. Mori, T., O'Keefe, B.R., Sowder, R.C. 2nd, Bringans, S., Gardella, R., Berg, S., Cochran, P., Turpin, J.A., Buckheit, R.W. Jr., McMahon, J.B., Boyd, M.R., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem 280 (2005), 9345–9353.
125. Mufhandu, H.T., Gray, E.S., Madiga, M.C., Tumba, N., Alexandre, K.B., Khoza, T., Wibmer, C.K., Moore, P.L., Morris, L., Khati, M., UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. J. Virol. 86 (2012), 4989–4999.
126. Ndesendo, V.M., Pillay, V., Choonara, Y.E., Buchmann, E., Bayever, D.N., Meyer, L.C., A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech 9 (2008), 505–520.
127. Nel, A., Bekker, L.G., Bukusi, E., Hellstrm, E., Kotze, P., Louw, C., Martinson, F., Masenga, G., Montgomery, E., Ndaba, N., van der Straten, A., van Niekerk, N., Woodsong, C., Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in Sub-Saharan Africa. PLoS One, 11, 2016, e0147743.
128. Nel, A., Haazen, W., Nuttall, J., Romano, J., Rosenberg, Z., van Niekerk, N., A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS 28 (2014), 1479–1487.
129. Neurath, A.R., Strick, N., Jiang, S., Li, Y.Y., Debnath, A.K., Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of “dead-end” gp41 six-helix bundles. BMC Infect. Dis., 2, 2002, 6.
130. Nimjee, S.M., Rusconi, C.P., Sullenger, B.A., Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56 (2005), 555–583.
131. Norvell, M.K., Benrubi, G.I., Thompson, R.J., Investigation of microtrauma after sexual intercourse. J. Reprod. Med 29 (1984), 269–271.
132. O'Hanlon, D.E., Moench, T.R., Cone, R.A., Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One, 8, 2013, e80074.
133. O'Hara, B.M., Olson, W.C., HIV entry inhibitors in clinical development. Curr. Opin. Pharmacol. 2 (2002), 523–528.
134. O'Keefe, B.R., Vojdani, F., Buffa, V., Shattock, R.J., Montefiori, D.C., Bakke, J., Mirsalis, J., d'Andrea, A.L., Hume, S.D., Bratcher, B., Saucedo, C.J., McMahon, J.B., Pogue, G.P., Palmer, K.E., Scalable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. USA 106 (2009), 6099–6104.
135. Padian, N.S., van der Straten, A., Ramjee, G., Chipato, T., de Bruyn, G., Blanchard, K., Shiboski, S., Montgomery, E.T., Fancher, H., Cheng, H., Rosenblum, M., van der Laan, M., Jewell, N., McIntyre, J., Team, M., Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 370 (2007), 251–261.
136. Perotti, M.E., Pirovano, A., Phillips, D.M., Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development. Biol. Reprod. 69 (2003), 933–939.
137. Piguet, V., Sattentau, Q., Dangerous liaisons at the virological synapse. J. Clin. Investig. 114 (2004), 605–610.
138. Piret, J., Lamontagne, J., Bestman-Smith, J., Roy, S., Gourde, P., Desormeaux, A., Omar, R.F., Juhasz, J., Bergeron, M.G., In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses. J. Clin. Microbiol. 38 (2000), 110–119.
139. Pohlmann, S., Baribaud, F., Doms, R.W., DC-SIGN and DC-SIGNR: helping hands for HIV. Trends Immunol. 22 (2001), 643–646.
140. Pohlmann, S., Baribaud, F., Lee, B., Leslie, G.J., Sanchez, M.D., Hiebenthal-Millow, K., Munch, J., Kirchhoff, F., Doms, R.W., DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J. Virol. 75 (2001), 4664–4672.
141. Popik, W., Alce, T.M., Au, W.C., Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J. Virol. 76 (2002), 4709–4722.
142. Pozzetto, B., Delezay, O., Brunon-Gagneux, A., Hamzeh-Cognasse, H., Lucht, F., Bourlet, T., Current and future microbicide approaches aimed at preventing HIV infection in women. Expert Rev. Anti-Infect. Ther. 10 (2012), 167–183.
143. Prakash, M., Kapembwa, M.S., Gotch, F., Patterson, S., Higher levels of activation markers and chemokine receptors on T lymphocytes in the cervix than peripheral blood of normal healthy women. J. Reprod. Immunol. 52 (2001), 101–111.
144. Prakash, M., Kapembwa, M.S., Gotch, F., Patterson, S., Chemokine receptor expression on mucosal dendritic cells from the endocervix of healthy women. J. Infect. Dis. 190 (2004), 246–250.
145. Primrose, R.J., Zaveri, T., Bakke, A.J., Ziegler, G.R., Moskowitz, H.R., Hayes, J.E., Drivers of vaginal drug delivery system acceptability from internet-based conjoint analysis. PLoS One, 11, 2016, e0150896.
146. Proske, D., Blank, M., Buhmann, R., Resch, A., Aptamers–basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. 69 (2005), 367–374.
147. Quinones-Mateu, M.E., Vanham, G., HIV microbicides: where are we now?. Curr. HIV Res. 10 (2012), 1–2.
148. Ramessar, K., Rademacher, T., Sack, M., Stadlmann, J., Platis, D., Stiegler, G., Labrou, N., Altmann, F., Ma, J., Stoger, E., Capell, T., Christou, P., Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Proc. Natl. Acad. Sci. USA 105 (2008), 3727–3732.
149. Ramjee, G., Microbicide research: current and future directions. Curr. Opin. HIV AIDS 5 (2010), 316–321.
150. Robbins, B.L., Srinivas, R.V., Kim, C., Bischofberger, N., Fridland, A., Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropy)ladenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 42 (1998), 612–617.
151. Roddy, R.E., Zekeng, L., Ryan, K.A., Tamoufe, U., Weir, S.S., Wong, E.L., A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339 (1998), 504–510.
152. Rohan, L.C., Sassi, A.B., Vaginal drug delivery systems for HIV prevention. AAPS J. 11 (2009), 78–87.
153. Rosenberg, Y., Sack, M., Montefiori, D., Forthal, D., Mao, L., Hernandez-Abanto, S., Urban, L., Landucci, G., Fischer, R., Jiang, X., Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One, 8, 2013, e58724.
154. Sassi, A.B., Cost, M.R., Cole, A.L., Cole, A.M., Patton, D.L., Gupta, P., Rohan, L.C., Formulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product. Antimicrob. Agents Chemother. 55 (2011), 2282–2289.
155. Savina, A., Jancic, C., Hugues, S., Guermonprez, P., Vargas, P., Moura, I.C., Lennon-Dumenil, A.M., Seabra, M.C., Raposo, G., Amigorena, S., NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 126 (2006), 205–218.
156. Schumacher, G.F.B., Kim, M.H., Hosseinian, A.H., Dupont, C., Immunoglobulins, proteinase inhibitors, albumin and lysozyme in human cervical mucus. Am. J. Obstet. Gynecol. 129 (1977), 629–636.
157. Schwartz, J.L., Kovalevsky, G., Lai, J.J., Ballagh, S.A., McCormick, T., Douville, K., Mauck, C.K., Callahan, M.M., A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex. Transm. Dis. 35 (2008), 414–419.
158. Schwartz, J.L., Poindexter, A., Schmitz, S.W., Mauck, C., Callahan, M.M., Male tolerance of ACIDFORM gel. Contraception 71 (2005), 443–446.
159. Scordi-Bello, I.A., Mosoian, A., He, C., Chen, Y., Cheng, Y., Jarvis, G.A., Keller, M.J., Hogarty, K., Waller, D.P., Profy, A.T., Herold, B.C., Klotman, M.E., Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother. 49 (2005), 3607–3615.
160. Shattock, R.J., Moore, J.P., Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 1 (2003), 25–34.
161. Sherer, N.M., Lehmann, M.J., Jimenez-Soto, L.F., Horensavitz, C., Pypaert, M., Mothes, W., Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat. Cell Biol. 9 (2007), 310–315.
162. Shukair, S.A., Allen, S.A., Cianci, G.C., Stieh, D.J., Anderson, M.R., Baig, S.M., Gioia, C.J., Spongberg, E.J., Kauffman, S.M., McRaven, M.D., Lakougna, H.Y., Hammond, C., Kiser, P.F., Hope, T.J., Human cervicovaginal mucus contains an activity that hinders HIV-1 movement. Mucosal Immunol. 6 (2013), 427–434.
163. Shum, K.T., Zhou, J., Rossi, J.J., Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals 6 (2013), 1507–1542.
164. Skoler-Karpoff, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M.G., Friedland, B., Govender, S., De Kock, A., Cassim, N., Palanee, T., Dozier, G., Maguire, R., Lahteenmaki, P., Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 1977–1987.
165. Smith, S.M., Baskin, G.B., Marx, P.A., Estrogen protects against vaginal transmission of simian immunodeficiency virus. J. Infect. Dis. 182 (2000), 708–715.
166. Spence, P., Nel, A., van Niekerk, N., Derrick, T., Wilder, S., Devlin, B., Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence. J. Pharm. Biomed. Anal. 125 (2016), 94–100.
167. Spira, A.I., Marx, P.A., Patterson, B.K., Mahoney, J., Koup, R.A., Wolinsky, S.M., Ho, D.D., Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183 (1996), 215–225.
168. Stein, S.E.G., Transmission and epidemiology. Richman, D.D., (eds.) Human Immunodeficiency Virus, 2003, International Medical Press, London.
169. Tabet, S.R., Callahan, M.M., Mauck, C.K., Gai, F., Coletti, A.S., Profy, A.T., Moench, T.R., Soto-Torres, L.E., Poindexter, I.A., Frezieres, R.G., Walsh, T.L., Kelly, C.W., Richardson, B.A., Van Damme, L., Celum, C.L., Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J. Acquir. Immune Defic. Syndr. 33 (2003), 476–483.
170. Taher, S.E., Inder, J.W., Soltan, S.A., Eliahoo, J., Edmonds, D.K., Bennett, P.R., Prostaglandin E2 vaginal gel or tablets for the induction of labour at term: a randomised controlled trial. BJOG: Int. J. Obstet. Gynaecol. 118 (2011), 719–725.
171. Tao, W., Richards, C., Hamer, D., Enhancement of HIV infection by cellulose sulfate. AIDS Res. Hum. Retrovir. 24 (2008), 925–929.
172. Temme, J.S., Krauss, I.J., SELMA: selection with modified aptamers. Curr. Protoc. Chem. Biol. 7 (2015), 73–92.
173. Tevi-Benissan, C., Belec, L., Levy, M., Schneider-Fauveau, V., Si Mohamed, A., Hallouin, M.C., Matta, M., Gresenguet, G., In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin. Diagn. Lab. Immunol. 4 (1997), 367–374.
174. Thurman, A.R., Clark, M.R., Hurlburt, J.A., Doncel, G.F., Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int. J. Women's Health 5 (2013), 695–708.
175. Torre, V.S., Marozsan, A.J., Albright, J.L., Collins, K.R., Hartley, O., Offord, R.E., Quinones-Mateu, M.E., Arts, E.J., Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J. Virol. 74 (2000), 4868–4876.
176. Tremblay, C.L., Kollmann, C., Giguel, F., Chou, T.C., Hirsch, M.S., Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J. Acquir. Immune Defic. Syndr. 25 (2000), 99–102.
177. Tsai, C.C., Emau, P., Jiang, Y., Agy, M.B., Shattock, R.J., Schmidt, A., Morton, W.R., Gustafson, K.R., Boyd, M.R., Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retrovir. 20 (2004), 11–18.
178. Tsai, C.C., Emau, P., Jiang, Y., Tian, B., Morton, W.R., Gustafson, K.R., Boyd, M.R., Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retrovir. 19 (2003), 535–541.
179. Tsai, C.C., Follis, K.E., Sabo, A., Beck, T.W., Grant, R.F., Bischofberger, N., Benveniste, R.E., Black, R., Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270 (1995), 1197–1199.
180. Tuerk, C., Gold, L., Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (1990), 505–510.
181. Turpin, J.A., Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Investig. Drugs 11 (2002), 1077–1097.
182. Vacas-Cordoba, E., Maly, M., De la Mata, F.J., Gomez, R., Pion, M., Munoz-Fernandez, M.A., Antiviral mechanism of polyanionic carbosilane dendrimers against HIV-1. Int. J. Nanomed. 11 (2016), 1281–1294.
183. Vacas Cordoba, E., Arnaiz, E., Relloso, M., Sanchez-Torres, C., Garcia, F., Perez-Alvarez, L., Gomez, R., de la Mata, F.J., Pion, M., Munoz-Fernandez, M.A., Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission. AIDS 27 (2013), 1219–1229.
184. Vamvaka, E., Evans, A., Ramessar, K., Krumpe, L.R., Shattock, R.J., O'Keefe, B.R., Christou, P., Capell, T., Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro. Plant Cell Rep. 35 (2016), 1309–1319.
185. Van Damme, L., Govinden, R., Mirembe, F.M., Guedou, F., Solomon, S., Becker, M.L., Pradeep, B.S., Krishnan, A.K., Alary, M., Pande, B., Ramjee, G., Deese, J., Crucitti, T., Taylor, D., Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359 (2008), 463–472.
186. Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiegne-Traore, V., Uaheowitchai, C., Karim, S.S., Masse, B., Perriens, J., Laga, M., Group, C.O.L.S., Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360 (2002), 971–977.
187. Van Damme, L., Wright, A., Depraetere, K., Rosenstein, I., Vandersmissen, V., Poulter, L., McKinlay, M., Van Dyck, E., Weber, J., Profy, A., Laga, M., Kitchen, V., A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex. Transm. Infect. 76 (2000), 126–130.
188. van de Wijgert, J.H., Braunstein, S.L., Morar, N.S., Jones, H.E., Madurai, L., Strickfaden, T.T., Moodley, M., Aboobaker, J., Ndlovu, G., Ferguson, T.M., Friedland, B.A., Hart, C.E., Ramjee, G., Carraguard vaginal gel safety in HIV-positive women and men in South Africa. J. Acquir. Immune Defic. Syndr. 46 (2007), 538–546.
189. van der Straten, A., Panther, L., Laborde, N., Hoesley, C.J., Cheng, H., Husnik, M.J., Horn, S., Nel, A., Soto-Torres, L., Chen, B.A., Adherence and acceptability of a multidrug vaginal ring for HIV prevention in a phase I study in the United States. AIDS Behav., 2016.
190. Veazey, R.S., Klasse, P.J., Schader, S.M., Hu, Q., Ketas, T.J., Lu, M., Marx, P.A., Dufour, J., Colonno, R.J., Shattock, R.J., Springer, M.S., Moore, J.P., Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438 (2005), 99–102.
191. Veazey, R.S., Shattock, R.J., Pope, M., Kirijan, J.C., Jones, J., Hu, Q., Ketas, T., Marx, P.A., Klasse, P.J., Burton, D.R., Moore, J.P., Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9 (2003), 343–346.
192. Veselinovic, M., Neff, C.P., Mulder, L.R., Akkina, R., Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 432 (2012), 505–510.
193. Welch, B.D., Francis, J.N., Redman, J.S., Paul, S., Weinstock, M.T., Reeves, J.D., Lie, Y.S., Whitby, F.G., Eckert, D.M., Hill, C.P., Root, M.J., Kay, M.S., Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol. 84 (2010), 11235–11244.
194. Wheeler, L.A., Trifonova, R., Vrbanac, V., Basar, E., McKernan, S., Xu, Z., Seung, E., Deruaz, M., Dudek, T., Einarsson, J.I., Yang, L., Allen, T.M., Luster, A.D., Tager, A.M., Dykxhoorn, D.M., Lieberman, J., Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J. Clin. Investig. 121 (2011), 2401–2412.
195. Wheeler, L.A., Vrbanac, V., Trifonova, R., Brehm, M.A., Gilboa-Geffen, A., Tanno, S., Greiner, D.L., Luster, A.D., Tager, A.M., Lieberman, J., Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol. Ther. 21 (2013), 1378–1389.
196. Woolfson, A.D., Malcolm, R.K., Morrow, R.J., Toner, C.F., McCullagh, S.D., Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int. J. Pharm. 325 (2006), 82–89.
197. Yeaman, G.R., Asin, S., Weldon, S., Demian, D.J., Collins, J.E., Gonzalez, J.L., Wira, C.R., Fanger, M.W., Howell, A.L., Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology 113 (2004), 524–533.
198. Zhang, Z., Blank, M., Schluesener, H.J., Nucleic acid aptamers in human viral disease. Arch. Immunol. Ther. Exp. 52 (2004), 307–315.
199. Zirafi, O., Kim, K.A., Roan, N.R., Kluge, S.F., Muller, J.A., Jiang, S., Mayer, B., Greene, W.C., Kirchhoff, F., Munch, J., Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides. Sci. Transl. Med., 6, 2014 262ra157.
200. Zussman, A., Lara, L., Lara, H.H., Bentwich, Z., Borkow, G., Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 17 (2003), 653–661.